Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-29T13:09:30.772Z Has data issue: false hasContentIssue false
  • English
  • Français

Risperidone therapy in the control of behavioural disturbances in patients with learning disability

Published online by Cambridge University Press:  13 June 2014

Dhanapal Natarajan ,
Alberto Jarabo Martin  and
Dorothy Tesh
Dhanapal Natarajan
Affiliation:
St Cadoc's Hospital, Lodge Road, Caerleon, Newport NP6 1XQ, Wales
Dorothy Tesh
Affiliation:
Lea Castle Hospital, Kidderminster, Worstershire, West Midlands DY10 3PP, England
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective: The objective of this audit to examine the effect of risperidone therapy in controlling some behavioural disturbances in people with learning disability.

Method: Retrospective analysis of various behavioural disturbances before and after beginning risperidone therapy (during the month before risperidone was started in each case, and during September 1994 in all cases).

Results: Risperidone was found to be effective in controlling various behaviour problems in 12 of 17 patients.

Conclusion: Risperidone may selectively influence behaviour problems secondary to possible underlying mental illness but not others. There was also some evidence that it was more effective in an average dose of 6-8mg/day, but was not beneficial in doses smaller or larger than this dose range.

Keywords

RisperidoneLearning disabilityBehavioural disturbances
Type
Audits
Information
Irish Journal of Psychological Medicine , Volume 14 , Issue 2 , June 1997 , pp. 69 - 71
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Roose, K, Gelders, YG, SLE, Heylen. Risperidone (R64766) in psychotic patients. A first clinical therapeutic exploration. Acta Psychiatr Belg 1988; 88: 233–41.Google ScholarPubMed
2.Mesotten, E, Suy, E, Pietquin, M, Burton, P, SLE, Heylen, Gelders, YG. Therapeutic effect and safety of increasing doses of risperidone (R64766) in psychotic patients. Psychopharmacology 1988; 89: 445–9.Google Scholar
3.Gelders, YG. Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiatry 1989; 155(5): 33–6.CrossRefGoogle Scholar
4.Meco, G, Bedini, L, Bonifati, V, Sonsini, U. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia: a single-blind crossover study versus placebo. Curr Ther Res 1989; 46: 876–83.Google Scholar
5.Gelders, YG, SLE, Heylen, Vanden Bussche, G, AJM, Reyntjens, PAJ, Janssen. Risperidone (R64766) in the treatment of psychotic patients: an open dose finding study. Pharma-copsychiatry 1990; 23: 206–11.CrossRefGoogle Scholar
6.Castelao, JF, Ferreira, L, Gelders, YG, SLE, Heylen. The efficacy of the D2 and 5-HT2 antagonist risperidone (R64766) in the treatment of chronic psychosis. An open dose finding study. Schizophrenic Res 1989; 2: 411–5.CrossRefGoogle Scholar
7.Bersani, G, Bressa, GM, Meco, G, Arini, S, Pozzi, F. Combined serotonin 5-HT2 and dopamine-D2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R64766). Hum Psychopharmacol 1990; 5: 225–31.CrossRefGoogle Scholar
8.Claus, A, Bollen, J, DeCuyper, Het al.Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992: 85: 295–305.CrossRefGoogle ScholarPubMed
9.Wright, Elaine Catherine. The presentation of mental illness in mentally retarded adults. Br J Psychiatry 1982; 141: 496–502.CrossRefGoogle ScholarPubMed
10.Reid, AH. Diagnosis of psychiatric disorder in the severely and profoundly retarded patient. Jr Royal Soc Med 1980; 73(September).Google ScholarPubMed
11.Kirman, BH. Mental illness and mental handicap: Reflections on diagnostic problems and prevalence. In: FE, James and RP, Smith eds. Psychiatric illness and mental handicap. Ashford, Kent: Headley Brothers.Google Scholar
12.DeCuyper, H, Van Praag, HM, Verstraeten, D. The effects of milenperone on the aggressive behaviour of oligo-phrenic patients. A double-blind placebo controlled trial. Neuropsychobiology 1985; 13: 101–5.CrossRefGoogle Scholar
13.Murti Rao, J, Cowie, VA, Mathew, B. Tardive dyskinesia in neuroleptic medicated mentally handicapped subjects. Acta psychiatric scand 1987; 76: 507–13.Google Scholar
14.Murti Rao, J, Cowie, VA, Mathew, B. Neuroleptic induced parkinsonian side effects in the mentally handicapped 1989; 33: 81–6.Google Scholar
15.JCJ, Van Hemert. Pipamperone (Dipiperon) in troublesome mental retardates: a double-blind placebo controlled cross-over study with long term follow up. Acta Psychiatr Scand 1975; 52: 237–45.Google Scholar
16.Deberdt, R. Pipamperone (Dipiperon) in the treatment of behaviour disorders. A large scale multicentre evaluation. Acta Psychiatr Belg 1976; 76: 157–66.Google ScholarPubMed
17.Haegeman, J, Duyck, F. A retrospective evaluation of pipamperone (Dipiperon) in the treatment of behavioural deviations in severely mentally handicapped. Acta Psychiatr Belg 1978; 78: 392–98.Google ScholarPubMed
18.Vanden Borre, R, Vermote, R, Buttiens, Met al.Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo controlled cross-over study. Acta Psychiatr Scand 1993: 87: 167–71.CrossRefGoogle ScholarPubMed